Mesenchymal Stromal Cells Uptake and Release Paclitaxel without Reducing its Anticancer Activity

Author(s): Massimo Mariotti, Renato Colognato, Marco Rimoldi, Manuela Rizzetto, Francesca Sisto, Valentina Cocce, Arianna Bonomi, Eugenio Parati, Giulio Alessandri, Renzo Bagnati, Augusto Pessina

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 15 , Issue 3 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


To improve the drug delivery efficiency on target cells, many strategies have been developed including Mesenchymal Stromal Cells (MSCs) approaches. In a previous study, we found that bone-marrow-derived MSCs (BM-MSCs) were able to incorporate and release the anti-tumor and anti-angiogenic drug, Paclitaxel (PTX). In this study, we evaluated the stability of PTX in standard cell culture conditions by analyzing the metabolites produced by MSCs after their incorporation of the drug. We are able to show that MSCs do not release either 3-OH-PTX or 6-OH-PTX metabolites (having a lower anticancer activity) but release an active PTX molecule together with the isomer 7-Epitaxol, is known to maintain the whole biological activity. This confirms that the simple procedure of MSCs priming with a drug (without any genetic cell manipulation), in our case PTX, does not modify the activity of the molecule and provides a new biological-device to carry and deliver PTX in tumor sites, by contributing to improve drug efficacy and target selectivity in cancer therapy.

Keywords: Anti-tumor activity, cancer, drug delivery, mesenchymal stromal cell, paclitaxel.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 01 March, 2015
Page: [400 - 405]
Pages: 6
DOI: 10.2174/1871520614666140618113441
Price: $65

Article Metrics

PDF: 36